Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis
46 patients around the world
Available in Mexico
This phase 2 trial will explore the efficacy of a single dose of vinblastine (6mg/m2) to
leukoreduce patients with newly diagnosed AML and hyperleukocytosis. Patients will be
allocated 1:1 into two groups: intravenous single dose vinblastine or oral hydroxiurea
(50mg/kg/day until response or induction chemotherapy). Effective leukoreduction and safety
parameters will be compared.